HighTower Advisors LLC Grows Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

HighTower Advisors LLC increased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXXFree Report) by 4.5% during the 3rd quarter, HoldingsChannel reports. The fund owned 34,217 shares of the company’s stock after acquiring an additional 1,468 shares during the quarter. HighTower Advisors LLC’s holdings in IDEXX Laboratories were worth $14,948,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the business. Pathstone Family Office LLC lifted its stake in shares of IDEXX Laboratories by 49.8% in the third quarter. Pathstone Family Office LLC now owns 11,001 shares of the company’s stock worth $4,810,000 after acquiring an additional 3,656 shares in the last quarter. Vanguard Personalized Indexing Management LLC lifted its stake in shares of IDEXX Laboratories by 7.5% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 8,171 shares of the company’s stock worth $3,573,000 after acquiring an additional 569 shares in the last quarter. Van ECK Associates Corp lifted its stake in shares of IDEXX Laboratories by 2.0% in the third quarter. Van ECK Associates Corp now owns 13,987 shares of the company’s stock worth $6,116,000 after acquiring an additional 276 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of IDEXX Laboratories by 1.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 462,535 shares of the company’s stock worth $202,253,000 after acquiring an additional 5,044 shares in the last quarter. Finally, Washburn Capital Management Inc. lifted its stake in shares of IDEXX Laboratories by 3.9% in the third quarter. Washburn Capital Management Inc. now owns 1,587 shares of the company’s stock worth $694,000 after acquiring an additional 60 shares in the last quarter. Institutional investors and hedge funds own 86.85% of the company’s stock.

Insider Transactions at IDEXX Laboratories

In other news, CEO Jonathan Jay Mazelsky sold 7,128 shares of the business’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $513.05, for a total transaction of $3,657,020.40. Following the completion of the transaction, the chief executive officer now directly owns 79,233 shares in the company, valued at $40,650,490.65. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CFO Brian P. Mckeon sold 23,326 shares of the stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $570.01, for a total transaction of $13,296,053.26. Following the completion of the sale, the chief financial officer now owns 29,718 shares in the company, valued at approximately $16,939,557.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Jonathan Jay Mazelsky sold 7,128 shares of the stock in a transaction on Monday, December 4th. The shares were sold at an average price of $513.05, for a total value of $3,657,020.40. Following the sale, the chief executive officer now owns 79,233 shares of the company’s stock, valued at approximately $40,650,490.65. The disclosure for this sale can be found here. Over the last three months, insiders sold 62,288 shares of company stock worth $34,600,528. Company insiders own 2.11% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on IDXX. StockNews.com raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Wednesday, December 20th. William Blair reissued an “outperform” rating on shares of IDEXX Laboratories in a report on Friday, January 5th. BNP Paribas began coverage on IDEXX Laboratories in a report on Thursday, December 7th. They issued an “outperform” rating and a $602.00 price objective for the company. JPMorgan Chase & Co. boosted their price objective on IDEXX Laboratories from $600.00 to $630.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Finally, Stifel Nicolaus lowered their price objective on IDEXX Laboratories from $500.00 to $460.00 and set a “hold” rating for the company in a report on Monday, October 30th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $591.50.

Check Out Our Latest Stock Report on IDXX

IDEXX Laboratories Stock Down 1.2 %

NASDAQ:IDXX opened at $565.56 on Tuesday. The firm has a market capitalization of $47.00 billion, a PE ratio of 56.16, a price-to-earnings-growth ratio of 3.14 and a beta of 1.25. The stock has a 50 day moving average of $541.90 and a 200-day moving average of $491.06. IDEXX Laboratories, Inc. has a 52 week low of $372.50 and a 52 week high of $579.68. The company has a current ratio of 1.57, a quick ratio of 1.17 and a debt-to-equity ratio of 0.42.

IDEXX Laboratories (NASDAQ:IDXXGet Free Report) last issued its quarterly earnings data on Monday, February 5th. The company reported $2.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.12 by $0.20. The business had revenue of $901.60 million during the quarter, compared to the consensus estimate of $891.88 million. IDEXX Laboratories had a return on equity of 71.66% and a net margin of 23.08%. The business’s revenue was up 8.8% on a year-over-year basis. During the same period in the previous year, the firm posted $2.05 earnings per share. Analysts predict that IDEXX Laboratories, Inc. will post 11.13 EPS for the current year.

IDEXX Laboratories Profile

(Free Report)

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Read More

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXXFree Report).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.